INTELLIGENT BIO SOLUTIONS IN (INBS) Fundamental Analysis & Valuation

NASDAQ:INBS • US36151G7097

Current stock price

2.62 USD
+0.16 (+6.5%)
Last:

This INBS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. INBS Profitability Analysis

1.1 Basic Checks

  • In the past year INBS has reported negative net income.
  • INBS had a negative operating cash flow in the past year.
  • INBS had negative earnings in each of the past 5 years.
  • INBS had a negative operating cash flow in each of the past 5 years.
INBS Yearly Net Income VS EBIT VS OCF VS FCFINBS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

  • The Return On Assets of INBS (-63.98%) is worse than 72.87% of its industry peers.
  • INBS has a worse Return On Equity (-101.81%) than 64.89% of its industry peers.
Industry RankSector Rank
ROA -63.98%
ROE -101.81%
ROIC N/A
ROA(3y)-101.5%
ROA(5y)-80.79%
ROE(3y)-251.51%
ROE(5y)-185.33%
ROIC(3y)N/A
ROIC(5y)N/A
INBS Yearly ROA, ROE, ROICINBS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K 1.5K 2K 2.5K

1.3 Margins

  • With a Gross Margin value of 46.21%, INBS perfoms like the industry average, outperforming 40.96% of the companies in the same industry.
  • INBS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INBS Yearly Profit, Operating, Gross MarginsINBS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1M -2M -3M

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. INBS Health Analysis

2.1 Basic Checks

  • INBS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, INBS has more shares outstanding
  • INBS has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, INBS has an improved debt to assets ratio.
INBS Yearly Shares OutstandingINBS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 200K 400K 600K
INBS Yearly Total Debt VS Total AssetsINBS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

2.2 Solvency

  • Based on the Altman-Z score of -6.29, we must say that INBS is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of INBS (-6.29) is worse than 75.53% of its industry peers.
  • INBS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • INBS has a Debt to Equity ratio of 0.00. This is in the better half of the industry: INBS outperforms 73.40% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.29
ROIC/WACCN/A
WACC8.61%
INBS Yearly LT Debt VS Equity VS FCFINBS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M -10M 15M

2.3 Liquidity

  • A Current Ratio of 2.37 indicates that INBS has no problem at all paying its short term obligations.
  • INBS has a Current ratio (2.37) which is in line with its industry peers.
  • A Quick Ratio of 2.26 indicates that INBS has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.26, INBS perfoms like the industry average, outperforming 54.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.37
Quick Ratio 2.26
INBS Yearly Current Assets VS Current LiabilitesINBS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. INBS Growth Analysis

3.1 Past

  • INBS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.33%, which is quite impressive.
  • INBS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.14%.
  • The Revenue has been growing by 74.49% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)57.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.11%
Revenue 1Y (TTM)18.14%
Revenue growth 3Y91.13%
Revenue growth 5Y74.49%
Sales Q2Q%47.62%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y128%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year126.26%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INBS Yearly Revenue VS EstimatesINBS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
INBS Yearly EPS VS EstimatesINBS Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 0 -500 -1K -1.5K

More info and screens

Find the best growth stocksShow best growing peers

4

4. INBS Valuation Analysis

4.1 Price/Earnings Ratio

  • INBS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 7.34, which indicates a rather cheap valuation of INBS.
  • INBS's Price/Forward Earnings ratio is rather cheap when compared to the industry. INBS is cheaper than 97.87% of the companies in the same industry.
  • INBS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 37.96.
Industry RankSector Rank
PE N/A
Fwd PE 7.34
INBS Price Earnings VS Forward Price EarningsINBS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INBS Per share dataINBS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15

4.3 Compensation for Growth

  • INBS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. INBS Dividend Analysis

5.1 Amount

  • INBS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INBS Fundamentals: All Metrics, Ratios and Statistics

INTELLIGENT BIO SOLUTIONS IN

NASDAQ:INBS (4/14/2026, 10:33:39 AM)

2.62

+0.16 (+6.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07
Earnings (Next)N/A
Inst Owners0.28%
Inst Owner Change0%
Ins Owners2.8%
Ins Owner Change16.13%
Market Cap5.24M
Revenue(TTM)3.58M
Net Income(TTM)-11.29M
Analysts85.71
Price TargetN/A
Short Float %2.33%
Short Ratio0.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-80.73%
Min Revenue beat(2)-84.07%
Max Revenue beat(2)-77.38%
Revenue beat(4)0
Avg Revenue beat(4)-80.18%
Min Revenue beat(4)-84.07%
Max Revenue beat(4)-77.38%
Revenue beat(8)0
Avg Revenue beat(8)-65.95%
Revenue beat(12)0
Avg Revenue beat(12)-52.3%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.34
P/S 1.46
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)-15.13
EYN/A
EPS(NY)0.36
Fwd EY13.63%
FCF(TTM)-4.88
FCFYN/A
OCF(TTM)-4.69
OCFYN/A
SpS1.79
BVpS5.55
TBVpS3.91
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -63.98%
ROE -101.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.21%
FCFM N/A
ROA(3y)-101.5%
ROA(5y)-80.79%
ROE(3y)-251.51%
ROE(5y)-185.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.37
Quick Ratio 2.26
Altman-Z -6.29
F-Score4
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.11%
EPS Next Y128%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)18.14%
Revenue growth 3Y91.13%
Revenue growth 5Y74.49%
Sales Q2Q%47.62%
Revenue Next Year126.26%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-33.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.77%
OCF growth 3YN/A
OCF growth 5YN/A

INTELLIGENT BIO SOLUTIONS IN / INBS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for INTELLIGENT BIO SOLUTIONS IN?

ChartMill assigns a fundamental rating of 2 / 10 to INBS.


What is the valuation status of INTELLIGENT BIO SOLUTIONS IN (INBS) stock?

ChartMill assigns a valuation rating of 4 / 10 to INTELLIGENT BIO SOLUTIONS IN (INBS). This can be considered as Fairly Valued.


Can you provide the profitability details for INTELLIGENT BIO SOLUTIONS IN?

INTELLIGENT BIO SOLUTIONS IN (INBS) has a profitability rating of 0 / 10.


What is the earnings growth outlook for INTELLIGENT BIO SOLUTIONS IN?

The Earnings per Share (EPS) of INTELLIGENT BIO SOLUTIONS IN (INBS) is expected to grow by 128% in the next year.